<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125199</url>
  </required_header>
  <id_info>
    <org_study_id>UCAMCFE-0009</org_study_id>
    <nct_id>NCT04125199</nct_id>
  </id_info>
  <brief_title>Effects of Decohexaenoic Acid Supplementation on Markers of Inflammatory Muscle Damage</brief_title>
  <acronym>(EDA)</acronym>
  <official_title>Effects of Decohexaenoic Acid Supplementation on Markers of Inflammatory Muscle Damage Induced by Eccentric Exercise in Endurance Athletes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo-controlled, double-blind, placebo-controlled clinical trial consisting of
      15 triathletes in which it is intended to observe less inflammatory damage at the muscular
      level after performing eccentric exercises.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">December 22, 2016</completion_date>
  <primary_completion_date type="Actual">December 22, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>It was measured before and after consumption of the supplement. In each of the times it was measured four times. Before performing the eccentric exercises, just after, at 24 and 48 hours later.</time_frame>
    <description>Changes in the inflammatory marker: C-reactive protein (ml / dl). It is measured in venous blood by blood extraction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>muscle damage</measure>
    <time_frame>It was measured before and after consumption of the supplement. In each of the times it was measured four times. Before performing the eccentric exercises, just after, at 24 and 48 hours later.</time_frame>
    <description>Changes in markers of muscle damage will be measured by serum lactate dehydrogenase (IU / L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>connective tissue injury</measure>
    <time_frame>It was measured before and after consumption of the supplement. In each of the times it was measured four times. Before performing the eccentric exercises, just after, at 24 and 48 hours later.</time_frame>
    <description>changes in markers of connective tissue injury: serum collagenase. They will be measured by blood extraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological variables: LEUCOCITS AND PLATES</measure>
    <time_frame>It was measured before and after supplement consumption. In each of the times it was measured four times. 1: before performing the eccentric exercises, 2: just after, 3: at 24 hours after and 4: 48 hours later.</time_frame>
    <description>changes in the hematological profile. The samples are analyzed by the laboratory analyzer: BA 400 BioSystems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical variables</measure>
    <time_frame>It was measured before and after consumption of the supplement. In each of the times it was measured four times. Before performing the eccentric exercises, just after, at 24 and 48 hours later.</time_frame>
    <description>changes in lipid profile: : basal glycemia(mg/dl), lipid profile: total cholesterol (mg / dl), high density lipoprotein (mg / dl), low density lipoprotein (mg / dl), triglycerides (mg / dl), atherogenic index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variable for the evaluation of fatigue: Subjective perception test of Borg's effort</measure>
    <time_frame>at the end of the stress test with the multipower. It was measured three times. 1: at the end of the test, 2: at 24 hours, 3: at 48 hours.</time_frame>
    <description>change in the perception of fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perception of pain through the analog visual scale.</measure>
    <time_frame>at the end of the stress test with the multipower. It was measured three times. 1: at the end of the test, 2: at 24 hours, 3: at 48 hours.</time_frame>
    <description>changes in the perception of muscle pain. Muscle pain will be measured from 0 (no pain), to 10 (unbearable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isokinetic variables</measure>
    <time_frame>Twice. One, before the consumption of the product under study and another after the consumption of the product. It was measured after 10 weeks.</time_frame>
    <description>changes in isokinetic variables: Peak torque, peak torque or force moment in extension and flexion in the different muscles involved and at the different measurement moments .It is measured in volts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric variables</measure>
    <time_frame>Two measurements. One, before the consumption of the product under study and another at 8 weeks of product consumption.</time_frame>
    <description>Weight (Kg), size (cm), BMI kg / m2. Perimeters (measured in cm): (waist, hip, waist / hip index, relaxed biceps, contracted biceps, medial thigh, twin or calf).Folds (mm) (tricipítal, subscapular, suprailiac anterior or supraspinal, abdominal, quadricipital or thigh, leg or calf medial, bicipital, iliocrestal).
Diameters (cm) (radiocubital or wrist biestiloid, humeral or elbow bicpicondiolo, femoral or knee bicondiol).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impedancemetric variables</measure>
    <time_frame>Two measurements. One, before the consumption of the product under study and another at 8 weeks of product consumption.</time_frame>
    <description>fat mass, total water, lean mass (measured in%), muscle mass, bone mass (kg), basal metabolism (KJ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver safety variables</measure>
    <time_frame>It was measured before and after consumption of the supplement. In each of the times it was measured four times. Before performing the eccentric exercises, just after, at 24 and 48 hours later. One year</time_frame>
    <description>It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Sport</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>supplement consumption</intervention_name>
    <description>Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® * (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.
Placebo composition: Olive oil (each capsule is 700 mg).
Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.
Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days).</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male sex.

          -  Age: between 18 and 45 years.

          -  BMI ≤ 35 Kg / m2.

          -  Volunteers capable of understanding the clinical study, competent to grant written
             informed consent and willing to comply with the study procedures and requirements.

          -  Subjects who do not suffer from chronic diseases.

          -  Non-smoking subjects or less than 10 cigarettes a day.

          -  Subjects who have not consumed any type of NSAID within 48 hours prior to the study or
             during its development.

          -  Subjects without a history of administration of corticosteroids the previous month or
             during the study.

          -  Subjects without allergy to any of the products under investigation.

          -  Patients who have not modified their habits in the performance of physical activity
             during the study (injuries, injuries ...).

          -  Patients who have not modified their dietary habits during the previous month or
             intend to do so during the study.

        Exclusion Criteria:

          -  Subjects who do not consume medication or nutritional supplements with antioxidant and
             / or anti-inflammatory properties.

          -  Subjects who do not consume diets with abundant antioxidant and / or anti-inflammatory
             products.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Francisco Javier López Román</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

